Page last updated: 2024-11-04

tegafur and Hyperkeratosis Palmaris et Plantaris

tegafur has been researched along with Hyperkeratosis Palmaris et Plantaris in 4 studies

Research Excerpts

ExcerptRelevanceReference
"Tegafur is a prodrug of 5-FU and is a component of S-1, another oral fluoropyrimidine active in a variety of solid tumors."1.31Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. ( Elasmar, SA; Hoff, PM; Saad, ED, 2001)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jucglà, A1
Sais, G1
Navarro, M1
Peyri, J1
Rios-Buceta, L1
Buezo, GF1
Peñas, PF1
Dauden, E1
Fernandez-Herrera, J1
Garcia-Diez, A1
Won, YH1
Seo, JJ1
Kim, SJ1
Lee, SC1
Chun, IK1
Elasmar, SA1
Saad, ED1
Hoff, PM1

Reviews

1 review available for tegafur and Hyperkeratosis Palmaris et Plantaris

ArticleYear
Knuckle pad-like keratoderma: a new cutaneous side reaction induced by tegafur.
    International journal of dermatology, 1998, Volume: 37, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Gallbladder Neoplasms; Humans; Keratoderma, P

1998

Other Studies

3 other studies available for tegafur and Hyperkeratosis Palmaris et Plantaris

ArticleYear
Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur.
    Archives of dermatology, 1995, Volume: 131, Issue:3

    Topics: Adult; Drug Eruptions; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palm

1995
Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
    Acta dermato-venereologica, 1997, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Erythema; Female; Foot Dermatoses; Hand Dermatoses;

1997
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug

2001